Cologuard is the first and only U.S. Food and Drug Administration-approved noninvasive stool DNA screening test for colorectal cancer. It has been proven to find 92 percent of colorectal cancers in average risk patients.
Mercy is the first hospital in the St. Louis area to make this new option available, according to the report.
More articles on gastroenterology:
CCFA promotes Crohn’s, UC awareness week
14 key players in the endoscopy device market
ASGE awards Lafayette General Endoscopy Center quality certification
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.